19:17 EDT Cytokinetics (CYTK) falls 12% to $37.91 after FDA delays aficamten review
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics announces PDUFA action date for aficamten
- Insider Moves: HEICO, Pegasystems, Transdigm, Cytokinetics, LKQ
- Texas Instruments, Mondelez downgraded: Wall Street’s top analyst calls
- Cytokinetics initiated with an Overweight at Barclays
- Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive